Clinical trial of rebamipide tablets combined with rabeprazole sodium enteric -coated tablets in the treatment of chronic atrophic gastritis
10.13699/j.cnki.1001-6821.2018.19.009
- VernacularTitle:瑞巴派特片联合雷贝拉唑钠肠溶片治疗慢性萎缩性胃炎的临床研究
- Author:
Ying-Ying ZHUANG
1
;
Zi-Lan RAO
;
Tai-Yong FANG
;
Ling-Xing WANG
Author Information
1. 福建医科大学 附属第二医院消化科
- Keywords:
rebaprit tablet;
rabeprazole sodium enteric -coated tablet;
chronic atrophic gastritis;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(19):2273-2275
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of re-bamipide combined with rabeprazole sodium enteric -coated tablets in the treatment of chronic atrophic gastritis .Methods A total of 94 pa-tients with chronic atrophic gastritis were randomly divided into control and treatment groups with 47 cases per group.Control group was given riberazole 20 mg per time, qd, orally.Treatment group received rabe-prazole 0.1 g per time, tid, orally, on the basis of control group.Two groups were treated for 8 weeks. The clinical efficacy, pepsinogen (PG), endothelin (ET) and adverse drug reactions were compared be-tween two groups.Results After treatment, total effective rates of treat-ment and control groups were 93.62%( 44 cases/47 cases ) and 70.21%(33 cases/47 cases) with significant difference ( P<0.05 ) . After treatment, the main indexes of treatment and control groups were compared: PGⅠ were ( 127.38 ±13.96 ) and ( 103.84 ±13.58 ) μg· L-1, ET were (65.49 ±5.99 ) and ( 74.20 ±9.79 ) ng· L-1, there were statistically significant differences (all P<0.05).The adverse drug reactions of treatment group were liver dysfunction and skin rash , which in control group were diarrhea , rash and nausea and vomiting .The total incidence of adverse drug reactions were 6.38%and 14.89%without significant difference (P>0.05).Conclusion Rebamipide combined with rabeprazole sodium enteric-coated tablets has a definitive clinical efficacy in the treatment of chronic atrophic gastritis , which can effectively regulate the levels of PG and inhibit the expression of ET , without increasing the incidence of adverse drug reactions.
